Resolor (prucalopride)
- Region
- 🇪🇺 EU
- Active substance
- prucalopride
- Company
- Takeda Pharmaceuticals International AG Ireland
- Status
- Authorised
- Therapeutic area
- Constipation
- EU approval
- Wed 14 Oct 2009
- Application
- EMEA/H/C/001012
- ATC
- A06AX05
- Official record
- www.ema.europa.eu
Indication
Resolor is indicated for symptomatic treatment of chronic constipation in adults in whom laxatives fail to provide adequate relief.
Regulatory milestones
No milestones recorded in the last year.
Follow Resolor
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.